BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

"This is a vaccine that was developed without cutting corners from a company with 171 years of credentials," Pfizer CEO Albert Bourla said.

Pfizer's CEO hasn't gotten his Covid vaccine yet, saying he doesn't want to cut in line

Pfizer and the U.S. are working out details on timing, CEO Albert Bourla told CNBC's "Squawk Box" in an interview.

Pfizer negotiating with U.S. to provide an additional 100 million Covid vaccine doses, CEO says

"This has been a challenging process because there have been multiple conversations happening as recently as November," Dr. Scott Gottlieb told CNBC.

U.S. could have bought additional Pfizer vaccines in November but passed, says Pfizer board member

FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.

COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod

Pfizer CEO Albert Bourla on Monday said the company has not signed an agreement yet with the United States on providing 100 million more coronavirus vaccine doses in 2021, telling CNN it is still negotiating whether to deliver the drug in the second or third quarter of the year.

Pfizer CEO says still negotiating with U.S. on more coronavirus vaccines

Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. The companies said the results supported "the favorable safety profile and robust induction of virus-specific antibody responses.

Pfizer, BioNTech COVID-19 vaccine candidate study in Germany support safety profile

NEW YORK and MAINZ, GERMANY, December 14, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity. The results were published on the preprint server MedRxiv and are available here . BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. It has been authorized for emergency use for individuals 16 years of age and older in several countries around the world.

Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) plan to allow the participants in the COVID-19 vaccine trials to learn if they were part of the placebo group and offer them free shots, Bloomberg reports. What Happened: Pfizer, in an emailed statement to Bloomberg, said that both companies are providing voluntary options to COVID-19 vaccine clinical trial volunteers, who were part of the placebo group, to receive the vaccine at scheduled time points.

Pfizer Plans To Offer COVID-19 Vaccine To Placebo Group Trial Volunteers: Report

Moderna

Hint: It's a big number -- but not nearly big enough.

How Many COVID Vaccine Doses Will Pfizer and Moderna Distribute by Year-End?

Centers for Disease Control and Prevention Director Dr. Robert Redfield said Sunday that he signed the CDC's official recommendation for Americans 16 and older to use the Pfizer-BioNTech coronavirus vaccine and applauded the vaccine as a step to "help restore some normalcy to our lives and our country.".

CDC's Redfield officially recommends Pfizer coronavirus vaccine

Arcturus Therapeutics

Johnson & Johnson

Novavax

Vaxart

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

CVS Health

Walgreens

How Soon Will COVID Vaccines Be Available After FDA Authorization?

The first trucks carrying a COVID-19 vaccine for widespread use in the United States are set to pull out of a Michigan manufacturing plant Sunday.

Pfizer begins packing coronavirus vaccine shipments at Michigan facility

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). This ACIP vote follows the December 1, 2020, ACIP recommend

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older

The Advisory Committee on Immunization Practices, part of the Centers for Disease Control and Prevention, just voted to recommend Pfizer's coronavirus vaccine for everyone over age 16. The move further paves the way for the shots to be rolled out in the US, although CDC Director Robert Redfield still must accept the panel's recommendation.

A CDC panel just voted to recommend Pfizer's COVID-19 shot for people 16 years and older

The FDA just cleared the first Covid vaccine for emergency use. Within hours, FedEx and UPS will begin shipping 2.9 million doses across the country.

Pfizer's Covid vaccine ships within hours. Here's how the U.S. plans to get it to everyone

A key U.S. Centers for Disease Control and Prevention panel voted unanimously to recommend Pfizer-BioNTech's Covid-19 vaccine for people 16 years and older on Saturday.

CDC panel clears Pfizer Covid vaccine for people 16 years and older, clearing another pivotal hurdle

The vaccines are already being packaged, an official said.

Pfizer Covid Vaccine Expected To Arrive In All 50 States By Monday

Why the U.K. Beat the U.S. in Authorizing a COVID Vaccine

FDA Authorizes Pfizer and BioNTech's Coronavirus Vaccine

Now that the vaccine from Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) has been given the greenlight from the U.S. Food and Drug Administration, the companies have to scale up rapidly to meet demand. Why It Matters: BioNTech CEO Ugur Sahin in an interview with Reuters talked about the ramp-up production.

BioNTech CEO Ugur Sahin Talks About 'Manufacturing Challenge' Of Producing Enough COVID-19 Vaccines

Pfizer Inc. (NYSE: PFE) received emergency use authorisation from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine that it developed in collaboration with Germany's BioNTech on Friday. The first round of vaccination comprising 2.9 million doses will begin in the upcoming week and focus primarily on elderly patients and healthcare workers this month.

Pfizer's COVID-19 vaccine wins emergency use authorisation from the U.S. FDA

The U.S. became the fifth nation behind the U.K., Bahrain, Canada and Saudi Arabia to approve a coronavirus vaccine candidate for emergency use. The verdict from the drug regulator came swifter than even the rapid timeline expected by many.

Pfizer-BioNTech Gets FDA Nod For Emergency Use Of Coronavirus Vaccine; Deliveries To Begin Immediately

Albert Bourla and his team overcame unproven science and manufacturing bottlenecks; ‘you're asking for too much.'.

How Pfizer delivered a COVID vaccine in record time: Crazy deadlines, a pushy CEO

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against COVID-19 in individuals 16 years of age or older. The vaccine is now authorized under an Emergency Use Authorization (EUA) while Pfizer and BioNTech gather additional data and prepare to file a planned Biologics License Application (BLA) with the FDA for a possib

News for BioNTech SE Stock (BNTX)